You are here
Ivan O. Rosas, MD
Dr. Rosas’ main clinical research interest is to determine the natural history of early stages of pulmonary fibrosis in susceptible cohorts. Through extensive phenotyping of patients affected with sporadic Idiopathic Pulmonary Fibrosis (IPF), kindred members affected with Familial Pulmonary Fibrosis (FPF), and rheumatoid arthritis patients affected with secondary pulmonary fibrosis, his research has shown that early pulmonary fibrosis can be readily detected in populations at risk. More recently his research has focused on the incidence of early interstitial lung disease in smokers.
Dr. Rosas is Director of the Pulmonary Fibrosis Program at Lovelace Respiratory Research Institute and Assistant Professor of Medicine, Brigham and Women’s Hospital (BWH)/Harvard Medical School. Dr. Rosas is working with LRRI to develop new capabilities such as animal models to better understand mechanisms involved in the etiology and to search for effective therapies. Faculty, post doctoral fellows, and graduate/undergraduate students are shared between LRRI and BWH, as are facilities, and clinical and animal research resources.
Dr. Rosas’ translational research efforts have focused on identifying novel molecular targets for diagnosis and treatment of human pulmonary fibrosis. Using gene-expression micro-arrays and targeted proteomics of broncho-alveolar lavage and peripheral blood, his research group has identified increases in levels of Syndecan-2 and Matrix Metalloprotease -7 in the lungs and peripheral blood of patients affected with IPF, suggesting that these proteins may have a role in disease progression. Presently his bench research focuses on potential molecular mechanisms by which these proteins contribute to the development of human pulmonary fibrosis.
Dr. Rosas is a member of the BWH Hospital Interstitial Lung Disease Program and the BWH Lung Transplant Program. The BWH Interstitial Lung Disease Program provides multi-disciplinary outpatient and inpatient care to patients affected with diverse forms of pulmonary fibrosis. Patients undergo an extensive evaluation by a pulmonologist, rheumatologist, cardiologist, and if required, a thoracic surgeon. Once diagnosis is confirmed, patients are treated with standard of care approaches and are invited to participate in clinical research trials or translational research protocols.
BWH Profile: http://researchfaculty.brighamandwomens.org/BRIProfile.aspx?id=4155